title: Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease.
abstract: We quantified the amount of amyloid beta-peptide (Abeta) immunoreactivity as well as amyloid deposits in a large cohort of transgenic mice overexpressing the V717F human amyloid precursor protein (APP(V717F+/-) TG mice) with no, one, or two mouse apolipoprotein E (Apoe) alleles at various ages. Remarkably, no amyloid deposits were found in any brain region of APP(V717F+/-) Apoe(-/-) TG mice as old as 22 mo of age, whereas age-matched APP(V717F +/-) Apoe(+/-) and Apoe(+/+) TG mice display abundant amyloid deposition. The amount of Abeta immunoreactivity in the hippocampus was also markedly reduced in an Apoe gene dose-dependent manner (Apoe(+/+) > Apoe(+/-) >> Apoe(-/-)), and no Abeta immunoreactivity was detected in the cerebral cortex of APP(V717F+/-) Apoe(-/-) TG mice at any of the time points examined. The absence of apolipoprotein E protein (apoE) dramatically reduced the amount of both Abeta(1-40) and Abeta(1-42) immunoreactive deposits as well as the resulting astrogliosis and microgliosis normally observed in APP(V717F) TG mice. ApoE immunoreactivity was detected in a subset of Abeta immunoreactive deposits and in virtually all thioflavine-S-fluorescent amyloid deposits. Because the absence of apoE alters neither the transcription or translation of the APP(V717F) transgene nor its processing to Abeta peptide(s), we postulate that apoE promotes both the deposition and fibrillization of Abeta, ultimately affecting clearance of protease-resistant Abeta/apoE aggregates. ApoE appears to play an essential role in amyloid deposition in brain, one of the neuropathological hallmarks of Alzheimer's disease.
authors.affiliation: Neuroscience Discovery Research, Lilly Research Laboratories, Indianapolis, IN 46285, USA.
authors.forename: K R
authors.initials: KR
authors.lastname: Bales
authors.forename: T
authors.initials: T
authors.lastname: Verina
authors.forename: D J
authors.initials: DJ
authors.lastname: Cummins
authors.forename: Y
authors.initials: Y
authors.lastname: Du
authors.forename: R C
authors.initials: RC
authors.lastname: Dodel
authors.forename: J
authors.initials: J
authors.lastname: Saura
authors.forename: C E
authors.initials: CE
authors.lastname: Fishman
authors.forename: C A
authors.initials: CA
authors.lastname: DeLong
authors.forename: P
authors.initials: P
authors.lastname: Piccardo
authors.forename: V
authors.initials: V
authors.lastname: Petegnief
authors.forename: B
authors.initials: B
authors.lastname: Ghetti
authors.forename: S M
authors.initials: SM
authors.lastname: Paul
mesh_terms: D000544:Alzheimer Disease / Q000235:genetics / Q000473:pathology*; D000682:Amyloid / Q000302:isolation & purification / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D001057:Apolipoproteins E / Q000235:genetics* / Q000302:isolation & purification / Q000378:metabolism; D001921:Brain / Q000473:pathology*; D002540:Cerebral Cortex / Q000473:pathology; D004195:Disease Models, Animal; D005911:Gliosis; D006579:Heterozygote; D006624:Hippocampus / Q000473:pathology; D006720:Homozygote; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009457:Neuroglia / Q000378:metabolism
chemical_list: D000682:Amyloid; D016564:Amyloid beta-Protein Precursor; D001057:Apolipoproteins E